NDA 020931 · Pfizer
Tikosyn
Dofetilide · Oral · Antiarrhythmic
NovelLast checked: Nov 20, 2026Latest source record: Aug 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Oct 1, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
3 Phase 3, 0 recruiting
FAERS reports
10,514
6,255 serious, 812 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. For detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION .
What it is approved for
From the label in effect Apr 21, 2026.
INDICATIONS AND USAGE Maintenance of Normal Sinus Rhythm (Delay in AF/AFl Recurrence) TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES ). Conversion of Atrial Fibrillation/Flutter TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.
Mechanism: Mechanism of Action Dofetilide shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, I Kr . At concentrations covering several orders of magnitude, dofetilide blocks only I Kr with no relevant block of the other repolarizing potassium currents (e.g., I Ks , I K1 ). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- TIKOSYN · DOFETILIDE 0.25MG · CAPSULE, ORAL · Prescription · TE AB
- TIKOSYN · DOFETILIDE 0.5MG · CAPSULE, ORAL · Prescription · TE AB
- TIKOSYN · DOFETILIDE 0.125MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dofetilide" as an intervention, any sponsor and status, largest first.
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial FibrillationPivotal-lookingActive, not recruiting
Boston Scientific CorporationIndustry
NCT06096337 · 484 participants · Start Dec 28, 2023 · Primary completion Feb 4, 2026
Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone · For: Persistent Atrial Fibrillation
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 61 sites in all
- High Intensity Focused Ultrasound (HIFU) Ablation System StudyPivotal-lookingSuspended
ProRhythm, Inc.Industry
NCT00392106 · 240 participants (planned) · Start Apr 2006 · Primary completion Dec 2010
Drug: propafenone; flecainide and 3 more · For: Atrial Fibrillation
Sites: Fullerton, California; Los Angeles, California; Atlanta, Georgia · 21 sites in all
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial FibrillationPivotal-lookingCompleted
Biosense Webster, Inc.Industry
NCT00540787 · 112 participants · Start Aug 1, 2003 · Primary completion Jun 1, 2006
Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs · For: Paroxysmal Atrial Fibrillation
Sites: Birmingham, Alabama; Boston, Massachusetts; Columbus, Ohio · 6 sites in all
- A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation AblationPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT00408200 · 110 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: propafenone; flecainide; sotalol; dofetilide · For: Atrial Fibrillation
Sites: Philadelphia, Pennsylvania · 2 sites in all
Food and Drug Administration (FDA)Federal agency
NCT03070470 · 60 participants · Start Mar 14, 2017 · Primary completion Jun 26, 2017
Drug: Ranolazine; Verapamil and 4 more · For: Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
Sites: West Bend, Wisconsin
Gilead SciencesGilead Sciences (GILD)
NCT02365532 · 60 participants · Start Feb 2015 · Primary completion May 2015
Drug: GS-6615; Placebo to match GS-6615 and 2 more · For: Long QT Syndrome
Sites: West Bend, Wisconsin
Mayo ClinicAcademic, hospital or other
NCT00578617 · 60 participants · Start Sep 2006 · Primary completion Feb 2009
Drug: Rate Control; Rate Control and 12 more · For: Atrial Fibrillation; Arrhythmia
Sites: Birminham, Alabama; Los Angeles, California; Maywood, Illinois · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- atrial fibrillation1,071
- drug ineffective1,035
- dyspnoea622
- dizziness564
- fatigue536
- death485
- electrocardiogram qt prolonged447
- headache398
- diarrhoea330
- malaise323
- drug interaction298
- nausea296
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 249 |
| 2005 | 196 |
| 2006 | 156 |
| 2007 | 118 |
| 2008 | 81 |
| 2009 | 100 |
| 2010 | 681 |
| 2011 | 347 |
| 2012 | 487 |
| 2013 | 576 |
| 2014 | 708 |
| 2015 | 829 |
| 2016 | 947 |
| 2017 | 628 |
| 2018 | 650 |
| 2019 | 927 |
| 2020 | 566 |
| 2021 | 460 |
| 2022 | 417 |
| 2023 | 416 |
| 2024 | 455 |
| 2025 | 321 |
| 2026 | 199 |
Recalls
1 FDA enforcement reports for this application.
Dec 3, 2014 · Class II · Terminated
Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tikosyn (Dofetilide)
2024 spending
$663K
Beneficiaries
133
526 claims
Per beneficiary
$4,985
$10.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,403,027 |
| 2021 | $412,298 |
| 2022 | $640,212 |
| 2023 | $789,599 |
| 2024 | $663,038 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Kukendrarajah K, Ahmad M, Carrington M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Sex differences in drug-induced changes in ventricular repolarization.
Vicente J, Johannesen L, Mason JW, et al. · J Electrocardiol 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Vicente J, Johannesen L, Hosseini M, et al. · PLoS One 2016 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.